A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck

(2011) Athanassios Argiris et al.   CANCER

Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?

(2011) Fabrice Andre et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell type-dependent biomarker expression in adenoid cystic carcinoma

(2010) Diana Bell et al.   CANCER

Signaling pathways in adenoid cystic cancers: Implications for treatment

(2010) Anjali K. Gupta et al.   CANCER BIOLOGY & THERAPY

Other Paradigms

(2010) Walter Stadler   CANCER JOURNAL

Other Paradigms: Better Treatments Are Identified by Better Trials

(2010) Manish R. Sharma et al.   CANCER JOURNAL

Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance

(2010) Y. Mitani et al.   CLINICAL CANCER RESEARCH

154 Establishment and evaluation of patient-derived tumor models of adenoid cystic carcinoma: Effects of chemotherapeutics and targeted therapies on human ACC xenografts

(2010) F. Nieves et al.   EJC SUPPLEMENTS

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Bar the Windows but Open the Door to Randomization

(2010) Mark J. Ratain   JOURNAL OF CLINICAL ONCOLOGY

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

(2010) Rene Bruno et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Expression of c-kit and Slug correlates with invasion and metastasis of salivary adenoid cystic carcinoma

(2010) Yaling Tang et al.   ORAL ONCOLOGY

Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas

(2009) R Dahse et al.   BRITISH JOURNAL OF CANCER

Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

(2009) Y Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib

(2009) Laura Vidal et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Comparison of Power Between Randomized Discontinuation Design and Upfront Randomization Design on Progression-Free Survival

(2009) Pingfu Fu et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland

(2009) Lizette Vila et al.   MODERN PATHOLOGY

Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)

(2009) Laura D. Locati et al.   ORAL ONCOLOGY

Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck

(2009) M. Persson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients

(2008) L.-S. Tham et al.   CLINICAL CANCER RESEARCH

Vandetanib Inhibits Growth of Adenoid Cystic Carcinoma in an Orthotopic Nude Mouse Model

(2008) S. Choi et al.   CLINICAL CANCER RESEARCH

Optimising the design of phase II oncology trials: The importance of randomisation

(2008) Mark J. Ratain et al.   EUROPEAN JOURNAL OF CANCER

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study

(2008) L.D. Locati et al.   ORAL ONCOLOGY